First Time Loading...

Pacira Biosciences Inc
NASDAQ:PCRX

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
NASDAQ:PCRX
Watchlist
Price: 27.21 USD -0.4% Market Closed
Updated: May 6, 2024

Pacira Biosciences Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pacira Biosciences Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Pacira Biosciences Inc
NASDAQ:PCRX
Revenue
$675m
CAGR 3-Years
16%
CAGR 5-Years
15%
CAGR 10-Years
23%
Johnson & Johnson
NYSE:JNJ
Revenue
$85.6B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$45.5B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$55.1B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
1%
Merck & Co Inc
NYSE:MRK
Revenue
$61.4B
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Revenue
$35.9B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
5%

Pacira Biosciences Inc
Revenue Breakdown

Breakdown by Geography
Pacira Biosciences Inc

Not Available

Breakdown by Segments
Pacira Biosciences Inc

Total Revenue: 675m USD
100%
Net Product Sales: 672.2m USD
99.6%
Exparel: 538.1m USD
79.7%
Zilretta: 111.1m USD
16.5%
Iovera°: 19.7m USD
2.9%
Bupivacaine Liposome Injectable Suspension: 3.3m USD
0.5%
Royalty Revenue: 2.7m USD
0.4%
Show More
Show Less

See Also

What is Pacira Biosciences Inc's Revenue?
Revenue
675m USD

Based on the financial report for Dec 31, 2023, Pacira Biosciences Inc's Revenue amounts to 675m USD.

What is Pacira Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
23%

Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for Pacira Biosciences Inc have been 16% over the past three years , 15% over the past five years , and 23% over the past ten years .